Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week Looks At 2014 Takeout Targets

Executive Summary

The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.


Related Content

Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting
Bristol Gets Five Primed For Immuno-Oncology Expansion
Kythera Doubles Down On Double Chins With Bayer Buyback
Deals Of The Week: Novartis Places Bid To Dominate In Cancer
With Alkermes’ Transition Well Under Way, Commercial Expansion Is Next
Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer
NPS Executes On Ultra-Orphan Gattex Launch With FDA Approval In Hand
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts